|
Gene: KIAA0430 |
Gene summary for KIAA0430 |
Gene summary. |
Gene information | Species | Human | Gene symbol | KIAA0430 | Gene ID | 9665 |
Gene name | meiosis regulator and mRNA stability factor 1 | |
Gene Alias | KIAA0430 | |
Cytomap | 16p13.11 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9Y4F3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9665 | KIAA0430 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 6.72e-08 | 5.47e-01 | 0.1622 |
9665 | KIAA0430 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 4.32e-18 | 5.55e-01 | 0.1575 |
9665 | KIAA0430 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 4.45e-05 | 3.27e-01 | 0.1545 |
9665 | KIAA0430 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 3.32e-13 | 5.65e-01 | 0.1569 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KIAA0430 | SNV | Missense_Mutation | c.20C>A | p.Thr7Asn | p.T7N | Q9Y4F3 | protein_coding | deleterious_low_confidence(0.04) | benign(0.169) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
KIAA0430 | SNV | Missense_Mutation | c.443N>C | p.Val148Ala | p.V148A | Q9Y4F3 | protein_coding | deleterious_low_confidence(0.03) | benign(0.024) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
KIAA0430 | SNV | Missense_Mutation | c.3595N>C | p.Glu1199Gln | p.E1199Q | Q9Y4F3 | protein_coding | deleterious(0.02) | possibly_damaging(0.724) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
KIAA0430 | SNV | Missense_Mutation | novel | c.3961N>C | p.Glu1321Gln | p.E1321Q | Q9Y4F3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A62Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KIAA0430 | SNV | Missense_Mutation | rs372638277 | c.3802G>A | p.Val1268Ile | p.V1268I | Q9Y4F3 | protein_coding | tolerated(0.24) | benign(0.03) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KIAA0430 | SNV | Missense_Mutation | c.1454N>T | p.His485Leu | p.H485L | Q9Y4F3 | protein_coding | tolerated(0.29) | possibly_damaging(0.908) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
KIAA0430 | SNV | Missense_Mutation | rs200947981 | c.4864N>A | p.Val1622Ile | p.V1622I | Q9Y4F3 | protein_coding | tolerated(0.19) | benign(0.018) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
KIAA0430 | SNV | Missense_Mutation | c.3766G>A | p.Glu1256Lys | p.E1256K | Q9Y4F3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B6-A0RQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
KIAA0430 | SNV | Missense_Mutation | c.397N>C | p.Gly133Arg | p.G133R | Q9Y4F3 | protein_coding | tolerated_low_confidence(0.05) | probably_damaging(0.935) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
KIAA0430 | SNV | Missense_Mutation | c.3988C>G | p.Leu1330Val | p.L1330V | Q9Y4F3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |